BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 9559590)

  • 1. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
    Sitnik TM; Henderson BW
    Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
    Henderson BW; Sitnik-Busch TM; Vaughan LA
    Photochem Photobiol; 1999 Jul; 70(1):64-71. PubMed ID: 10420844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.
    Busch TM; Wileyto EP; Emanuele MJ; Del Piero F; Marconato L; Glatstein E; Koch CJ
    Cancer Res; 2002 Dec; 62(24):7273-9. PubMed ID: 12499269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
    Ericson MB; Sandberg C; Stenquist B; Gudmundson F; Karlsson M; Ros AM; Rosén A; Larkö O; Wennberg AM; Rosdahl I
    Br J Dermatol; 2004 Dec; 151(6):1204-12. PubMed ID: 15606516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.
    Wang HW; Rickter E; Yuan M; Wileyto EP; Glatstein E; Yodh A; Busch TM
    Photochem Photobiol; 2007; 83(5):1040-8. PubMed ID: 17880498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.
    Qiu H; Kim MM; Penjweini R; Finlay JC; Busch TM; Wang T; Guo W; Cengel KA; Simone CB; Glatstein E; Zhu TC
    Photochem Photobiol; 2017 Jul; 93(4):1115-1122. PubMed ID: 28083883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic effectiveness and vasoconstriction in hairless mouse skin after topical 5-aminolevulinic acid and single- or two-fold illumination.
    van der Veen N; Hebeda KM; de Bruijn HS; Star WM
    Photochem Photobiol; 1999 Dec; 70(6):921-9. PubMed ID: 10628304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluence rate as a modulator of PDT mechanisms.
    Henderson BW; Busch TM; Snyder JW
    Lasers Surg Med; 2006 Jun; 38(5):489-93. PubMed ID: 16615136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice.
    Anderson CY; Freye K; Tubesing KA; Li YS; Kenney ME; Mukhtar H; Elmets CA
    Photochem Photobiol; 1998 Mar; 67(3):332-6. PubMed ID: 9523532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.
    Wang HW; Putt ME; Emanuele MJ; Shin DB; Glatstein E; Yodh AG; Busch TM
    Cancer Res; 2004 Oct; 64(20):7553-61. PubMed ID: 15492282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
    Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
    Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats.
    Tsutsui H; MacRobert AJ; Curnow A; Rogowska A; Buonaccorsi G; Kato H; Bown SG
    Lasers Med Sci; 2002; 17(2):101-9. PubMed ID: 12111593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy of human squamous cell carcinoma in vitro and in xenografts in nude mice.
    Megerian CA; Zaidi SI; Sprecher RC; Setrakian S; Stepnick DW; Oleinick NL; Mukhtar H
    Laryngoscope; 1993 Sep; 103(9):967-75. PubMed ID: 8361317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma.
    Lilge L; Molpus K; Hasan T; Wilson BC
    Photochem Photobiol; 1998 Sep; 68(3):281-8. PubMed ID: 9747583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.
    Busch TM; Xing X; Yu G; Yodh A; Wileyto EP; Wang HW; Durduran T; Zhu TC; Wang KK
    Photochem Photobiol Sci; 2009 Dec; 8(12):1683-93. PubMed ID: 20024165
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Penjweini R; Kim MM; Ong YH; Zhu TC
    Phys Med Biol; 2020 Jan; 65(3):03LT01. PubMed ID: 31751964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
    Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC.
    van Geel IP; Oppelaar H; Marijnissen JP; Stewart FA
    Radiat Res; 1996 May; 145(5):602-9. PubMed ID: 8619026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Hypocrellin B in a human bladder tumor model in experimental photodynamic therapy: biodistribution, light dose and drug-light interval effects.
    Chin W; Lau W; Cheng C; Olivo M
    Int J Oncol; 2004 Sep; 25(3):623-9. PubMed ID: 15289863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.